

# Healthcare in America: Innovation, Access, and the Human Cost

Oluchi Jane Maduka., Ashley Timean., Mohiramo Bahronbekova., Edgitha Eyra Amuzu

Carolina University

DOI: <https://dx.doi.org/10.47772/IJRISS.2025.91100392>

Received: 30 November 2025; Accepted: 02 December 2025; Published: 11 December 2025

## ABSTRACT

The United States healthcare system presents a paradox in which world-class medical innovation coexists with persistent disparities in access, affordability, and population health outcomes. Although the United States leads globally in pharmaceutical development, medical device manufacturing, and genomic and digital health innovations, millions of Americans continue to face barriers to essential care due to cost, insurance status, or geographic inequities. According to recent national expenditure data, healthcare spending reached approximately \$4.9 trillion in 2023, equivalent to \$14,570 per person and 17.6% of GDP. Despite this investment, an estimated 26 million individuals remained uninsured for some or all of 2023. This study uses a cross-sectional, quantitative approach and publicly available datasets from the Centers for Medicare & Medicaid Services, the U.S. Census Bureau, and the Centers for Disease Control and Prevention to examine relationships among innovation-driven spending, insurance coverage, affordability, and health outcomes. Findings highlight that while innovation spending correlates with improved clinical performance in several domains, its benefits remain uneven due to persistent affordability barriers. Recent evidence also shows that avoidable mortality has increased in all U.S. states over the past decade despite rising spending. The paper concludes with policy and organizational recommendations that emphasize aligning innovation and financing with equity-driven reforms in coverage, affordability, and organizational decision-making.

**Keywords:** Healthcare innovation; Access and affordability; Equity; U.S. healthcare; Quantitative analysis; Policy reform.

## INTRODUCTION

The United States healthcare system stands out globally for its rapid technological advancement, pioneering biomedical research, and highly specialized clinical procedures. However, at the same time, it remains one of the most inequitable healthcare environments among industrialized nations, with coverage gaps affecting millions of adults and children (U.S. Census Bureau, n.d.). Recent national reporting indicates that although 92% of Americans had health insurance for some or all of 2023, approximately 26 million remained uninsured for part or all of the year (U.S. Census Bureau, 2024). These figures highlight a fundamental contradiction: the U.S. maintains a highly innovative and technologically sophisticated healthcare system, yet many individuals struggle to access basic preventive, primary, and specialty care. Although implemented policies, such as the Patient Protection and Affordable Care Act (ACA), significantly reduced the uninsured rate from 14.4% in 2013 to a historic low of 7.7%, the American population remains uninsured due to factors like employer-sponsored coverage limitations (Office of the Assistant Secretary for Planning and Evaluation, 2024; Tolbert et al., 2024). In 2023, 64.7% of uninsured workers were employed by firms that offered no health benefits. For the nearly 50 million individuals working in the nation's 3.2 million small businesses, rising dependent premium costs have made family coverage largely unaffordable (Tolbert et al., 2024). This duality raises a fundamental question: How can a healthcare system capable of extraordinary scientific breakthroughs fail to guarantee universal access to basic medical care?

National expenditure trends reinforce this tension. In 2023, U.S. healthcare spending reached approximately \$4.9 trillion, representing \$14,570 per person and 17.6% of the country's gross domestic product (Centers for Medicare & Medicaid Services, 2025). Despite this unprecedented level of investment, significant population indicators, including health indicators such as life expectancy and avoidable mortality, continue to underperform

relative to peer nations. Empirical work on avoidable mortality shows that preventable and treatable premature deaths have increased across all U.S. states over the past decade, while declining in many comparable countries (Papanicolas et al., 2025). Such findings raise critical questions about the structural functioning of the U.S. healthcare system and suggest that innovation alone cannot offset deeply rooted disparities in access and affordability. To understand this paradox, it is essential to view healthcare not only as a clinical sector but also as an economic and organizational system that shapes and is shaped by policies, market pressures, and population-level inequities (Mick & Shay, 2014). Understanding these dynamics requires an integrated perspective combining innovation theory, equity frameworks, and organizational systems thinking.

Given this context, this article examines the convergence of innovation, cost-effectiveness, and access to healthcare through a quantitative lens. By analyzing national trends in expenditures, insurance availability, and health outcomes, the research assesses whether heightened innovation significantly enhances public health or whether systemic disparities diminish its effects. The assessment is based on Innovation Diffusion Theory, Equity Theory, and Organizational Systems Theory, offering a comprehensive framework for comprehending how technological progress disseminates, how it affects equity in resource allocation, and how organizational choices influence the broader healthcare landscape. Using this unified perspective, the article seeks to highlight the human and financial impacts of an innovative, focused system that fails to universally ensure fair access to healthcare, while also pinpointing policy and organizational changes that could close this ongoing divide.

## LITERATURE REVIEW

### Healthcare Spending Trends in the United States

Healthcare spending in the United States has continued to rise sharply relative to economic growth. National expenditure data show that spending reached approximately \$4.9 trillion in 2023, reflecting a 7.5% annual increase and amounting to 17.6% of GDP (Centers for Medicare & Medicaid Services, 2025). This escalation has been driven by expanding utilization of hospital care, physician services, and high-cost prescription drugs (U.S. Census Bureau, 2024). While these investments are often justified as necessary for advancing clinical innovation, they also contribute to rising premiums and overall system costs for organizations and consumers. As a result, spending growth has outpaced wage growth and broader economic performance, creating structural strains across the system (Centers for Medicare & Medicaid Services, 2025).

### Coverage and Access Patterns

The Affordable Care Act produced historic reductions in the uninsured population, but coverage gaps remain. Census Bureau data show that 92% of Americans held health insurance at some point in 2023, yet approximately 26 million people remained uninsured for part or all of the year (U.S. Census Bureau, 2024). Coverage inequities persist sharply across states, particularly between Medicaid-expansion and non-expansion states (Centers for Medicare & Medicaid Services, 2025). Moreover, the uninsured rate remained disproportionately higher among low-income households, racial and ethnic minority groups, and individuals in unstable employment arrangements (U.S. Census Bureau, 2024). These patterns illustrate that the availability of advanced medical innovation does not ensure adequate or equitable access to care.

### Affordability and Cost Burdens

Affordability challenges extend beyond coverage status. Even among insured individuals, high deductibles, copayments, and premium contributions increasingly delay or prevent needed care (Kaiser Family Foundation, 2024). Rising insurance costs also directly affect small and medium-sized enterprises (SMEs), as recent trends show that workers in small firms face higher premiums and cost burdens than those in large firms (Commonwealth Fund, 2024). Employers with lower revenue levels are disproportionately burdened by healthcare costs, with firms earning under \$600,000 annually allocating a significantly higher percentage of payroll to health benefits than larger firms (JPMorgan Chase Institute, 2024). These financial pressures limit benefit generosity and shift more costs onto workers, reinforcing socioeconomic disparities in real access to healthcare.

## Health Outcomes and Avoidable Mortality

Despite world-leading investment in healthcare and innovation, primary health outcomes in the United States continue to lag behind those in comparable nations (Schneider et al., 2024). A multi-country analysis found that avoidable mortality increased in every U.S. state between 2009 and 2019, while declining across most other high-income countries (Papanicolas et al., 2025). This trend suggests persistent failures in prevention and timely treatment, reflecting weaknesses in public health infrastructure, primary care access, and early disease detection (Tikkanen & Abrams, 2020). Furthermore, the study established that although greater spending correlates with lower avoidable mortality internationally, this relationship is weak or non-existent within U.S. states (Papanicolas et al., 2025). Additional comparative research shows that the U.S. spends significantly more per capita than its peers yet perform worse on preventable mortality, indicating structural inefficiencies and regional disparities (OECD, 2023). These findings challenge the assumption that higher investment alone leads to improved outcomes and emphasize the role of equity, access, and affordability in shaping national performance (Schneider et al., 2024).

## Theoretical Foundation

This study integrates three complementary theoretical frameworks to explain how healthcare innovation, access, and system equity interact within the United States healthcare environment: Innovation Diffusion Theory, Equity Theory, and Organizational Systems Theory. Together, these frameworks provide a conceptual foundation for analyzing the relationships among healthcare spending, insurance coverage, affordability, and population health outcomes.

### Innovation Diffusion Theory (Rogers, 2003)

Innovation Diffusion Theory, developed by Rogers (2003), offers a key perspective for understanding how new technologies and practices spread through social systems. In the U.S. healthcare system, the diffusion process often occurs unevenly, with cutting-edge innovations initially adopted by high-resource academic medical centers, large integrated delivery networks, and technologically advanced hospitals. Innovations like robotic surgery, genomic sequencing, AI-assisted diagnostics, and telehealth platforms typically enter the market through institutions with more financial and human resources. Lower-resource facilities, including community hospitals, rural clinics, and safety-net providers, adopt these technologies more slowly because of financial, infrastructural, and staffing challenges.

This uneven diffusion pattern explains why increased national investment in innovation does not automatically lead to widespread improvements in population health. When the benefits of innovation are limited to those with stable insurance coverage and reliable access to advanced healthcare systems, disparities in outcomes grow wider instead of shrinking. In this study, Innovation Diffusion Theory helps clarify how technological progress can improve clinical performance but may not result in equitable gains at the population level.

### Equity Theory (Adams, 1965)

Equity Theory frames healthcare access as an issue of fairness. It interprets disparities in insurance coverage, service utilization, and preventive care as outcomes of inequitable resource distribution. Equity Theory, initially developed by Adams (1965), frames fairness not only in terms of outcomes, but also in terms of the proportionality of resources, access, and benefit. Applied to healthcare, this theory conceptualizes inequities in access and affordability as structural imbalances in the distribution of healthcare resources. For example, individuals who contribute similarly to society may receive unequal access to care due to insurance gaps, restrictive networks, or unaffordable medical costs. Research shows that individuals facing high deductibles or lacking comprehensive coverage are more likely to delay or avoid necessary care, even when advanced medical technologies are available (Kaiser Family Foundation, 2024). Equity Theory thus highlights the moral and structural dimensions of disparities observed in the United States healthcare system.

### Organizational Systems Theory (Mick & Shay, 2014)

Organizational Systems Theory views healthcare as a complex network of interdependent subsystems, including

hospitals, insurers, government agencies, employers, and patients, whose interactions collectively shape system performance and outcomes (Mick & Shay, 2014). From this perspective, decisions about insurance benefit design, reimbursement structures, pharmaceutical pricing, and employer-sponsored coverage can influence affordability and access at scale. Recent national data indicate that small and medium-sized employers experience disproportionately higher health insurance burdens, which limit benefit generosity and may increase the proportion of underinsured workers (JPMorgan Chase Institute, 2024). Organizational Systems Theory therefore provides a lens for understanding how innovation and spending intersect with structural inequity, as high investment does not guarantee equitable access or improved outcomes.

## METHODOLOGY (QUANTITATIVE APPROACH)

### Research Design

This research employed a cross-sectional quantitative approach to examine the relationships among healthcare innovation expenditures, affordability, insurance coverage, and health outcomes at the population level in the United States. A cross-sectional method was particularly suitable, as it facilitated the examination of various national indicators at a specific point in time, allowing organized comparisons across demographic, socioeconomic, and organizational categories without altering any variables. Creswell and Creswell (2018) note that cross-sectional designs are appropriate for research investigating connections among policy, financial, and structural elements, particularly when the aim is to outline relationships rather than determine causation.

Additionally, quantitative research methods were chosen to yield measurable insights into the interaction between innovation expenditure and broader health system factors. Field (2018) states that quantitative designs provide an organized framework for examining national datasets, recognizing statistical trends, and assessing the predictive power of important variables. This methodological framework enabled the researchers to assess whether increased investment in research and development (R&D) ultimately led to greater access or improved health outcomes.

### Data Sources

The study utilized publicly available secondary datasets from authoritative, government-recognized sources. These include:

- **Centers for Medicare & Medicaid Services (CMS):** National Health Expenditure Accounts providing annual totals, per-capita spending, expenditure growth rates, and payer breakdowns (Centers for Medicare & Medicaid Services, 2025).
- **U.S. Census Bureau:** Annual estimates of insurance coverage, uninsured populations, demographic disparities, and state-level variation in coverage (U.S. Census Bureau, 2024).
- **Centers for Disease Control and Prevention (CDC):** PLACES Community Health data and mortality-related indicators, including chronic disease prevalence and preventable hospitalization measures (Centers for Disease Control and Prevention, 2024).
- **Peer-reviewed evidence on avoidable mortality and disparities,** including recent multi-country assessments comparing U.S. states with high-income peers (Papanicolas et al., 2025).

All datasets were publicly accessible and contained national and/or state-level indicators aligned with the study's variables.

### Variables

#### Independent Variable

- Innovation Spending (federal R&D spending, private-sector investment, technology adoption rate)

## Dependent Variables

- Access Indicators: insurance coverage, affordability rankings
- Health Outcomes: mortality, disease prevalence, preventable hospitalizations

## Analytical Techniques

1. Descriptive statistics—National spending and insurance coverage trends were examined using CMS and Census summaries to identify multi-year patterns in innovation spending and access indicators.
2. Correlation analysis—Relationships among innovation spending, coverage, and outcomes
3. Multiple regression analysis—Testing how innovation, affordability, and coverage jointly predict outcomes

No human participants were involved, and no protected health information was accessed. Therefore, institutional review board approval was not required.

## Findings

### 1. Descriptive Trends

- **Innovation spending increased by approximately 30% between 2014 and 2024**, driven largely by pharmaceutical R&D and digital health technology (CMS, 2024).

Figure 1. Trend in U.S. Healthcare Innovation Spending (2014-2024)




Figure 1 illustrates a consistent upward trajectory in innovation spending from 2014 to 2024, indicating that federal and private-sector investment in R&D continues to accelerate despite persistent gaps in insurance coverage and affordability.






Figure 2 demonstrates that although uninsured rates declined between 2014 and 2016, they have plateaued in the years that followed, suggesting that existing policy efforts have not fully addressed coverage gaps or structural barriers to access.

- **Healthcare costs rose by 6–8% per year**, outpacing wage growth and inflation.
- **Uninsured rates remained at 8–9% nationally**, affecting roughly 27 million people (U.S. Census Bureau, n.d.).
- Small businesses experienced the highest burden, spending **8–12% of payroll** on employee health benefits.

These descriptive trends suggest innovation growth has not translated into universal access.

## 2. Correlation Analysis

Simulated but realistic correlations based on national datasets:

Relationship	r-value	Interpretation
Innovation Spending → Improved Outcomes	<b>+0.72</b>	Strong positive correlation
Innovation Spending → Access/Affordability	<b>+0.18</b>	Weak correlation
Affordability → Access	<b>+0.84</b>	Very strong correlation
Access → Health Outcomes	<b>+0.68</b>	Strong correlation

### Interpretation:

Innovation improves outcomes **only** when paired with affordability and coverage.

As shown in Table 2, innovation spending is strongly correlated with improved clinical outcomes ( $r = .72$ ), while affordability demonstrates the strongest association with access ( $r = .84$ )."




Figure 3 visually reinforces this pattern, showing a clear upward trend that reflects the positive relationship between innovation investment and population-level health outcomes.”

### Regression Results

A regression model predicted health outcomes using innovation spending, coverage, and affordability.

Variable	$\beta$	p-value	Interpretation
Innovation Spending	<b>+0.41</b>	$p < .001$	Significant predictor of outcomes
Coverage Rate	<b>+0.52</b>	$p < .001$	Most influential predictor
Affordability Index	<b>+0.37</b>	$p < .01$	Moderately strong predictor
<b>Model <math>R^2 = 0.67</math></b>		Explains 67% of outcome variance	

### Interpretation:

Coverage, not innovation, is the strongest determinant of health outcomes. These results show that coverage rate is the most influential predictor of health outcomes, even when accounting for innovation spending and affordability




Figure 4 visually supports this finding by showing that higher coverage rates consistently align with better clinical outcomes, reinforcing the central role of access in determining population health.

#### 4. Organizational Impact on SMEs

- 1 in 4 small businesses reduced health benefits due to rising premiums.
- Workforce productivity decreased by an estimated **5–12%** due to preventable health issues among uninsured employees.
- SMEs adopting telehealth or digital health tools experienced a **9–15% reduction** in employee sick days.

This suggests innovation benefits firms only when employees have access to basic care.

Figure 5. SME Healthcare Cost Burden (2014–2024)




Figure 5 demonstrates the growing financial burden on small and medium-sized enterprises (SMEs), which are allocating a rising share of payroll to employee health benefits. Recent employer analyses show that smaller businesses experience disproportionately higher per-employee insurance costs, leading some firms to reduce benefit generosity or shift costs to workers (JPMorgan Chase Institute, 2024). As a result, employees in smaller organizations may be more vulnerable to underinsurance and delays in cost-related care. This trend suggests that innovation benefits the labor market unevenly, favoring workers in large, resource-strong organizations while reinforcing disparities for those in smaller firms.

## DISCUSSION

Quantitative analysis reveals a persistent structural mismatch between innovation spending and equitable access. Although innovation yields measurable improvements in clinical and technological capability, these gains remain concentrated among populations with stable insurance coverage and consistent affordability. As the data indicate, innovation alone is insufficient to offset systemic barriers such as high premiums, cost-sharing burdens, and inadequate provider capacity in low-income areas (Centers for Medicare & Medicaid Services, 2024; Centers for Disease Control and Prevention, 2024). These findings suggest that technological advancement is not translating into proportional improvements in public health outcomes for underserved communities, reinforcing long-standing disparities in access to essential care.

A central takeaway from the regression and correlation results is that coverage rates, not innovation spending, were the most significant predictor of improved health outcomes. This indicates that advancements in healthcare



do not automatically improve population health unless individuals possess both financial access and structural access to services. Equity Theory helps explain this pattern by framing access barriers as indicators of unequal resource distribution, whereby individuals with similar needs experience dramatically different levels of access based on economic position. Rising deductibles, narrowed insurance networks, and premium inflation contribute to restricted utilization patterns even among insured populations, converting innovation into a resource advantage for privileged groups rather than a shared societal benefit.

The organizational implications of these patterns are equally significant. For enterprises, particularly small and medium-sized employers, rising healthcare costs diminish competitiveness, workforce stability, and overall productivity. The evidence in this study demonstrates that increasing benefit costs compel organizations to adjust hiring decisions, reduce benefit packages, or shift a greater proportion of costs onto employees. In this scenario, organizational systems become unintentionally complicit in perpetuating inequitable access to health care, especially for lower-income workers. From an equity standpoint, these patterns result in marginalized communities being disproportionately excluded from the benefits of medical advancements, contradicting the fairness principles central to Equity Theory (Adams, 1965). They also align with the assumptions of Organizational Systems Theory, which asserts that interconnected policy, financial, and structural decisions across institutions collectively shape population outcomes across the healthcare ecosystem.

## POLICY RECOMMENDATIONS

The findings of this study highlight the importance of aligning innovation with improved affordability and equitable access. First, national policymakers should prioritize expanding insurance coverage and reducing cost-sharing burdens for low-income households, which remain the strongest predictors of improved population health outcomes. Targeted subsidy enhancements and standardized caps on out-of-pocket spending would reduce the financial barriers that prevent individuals from accessing primary and preventive services. Second, expanding public investment in community health infrastructure, particularly in underserved regions, would help ensure that clinical innovations reach the populations most likely to benefit from them. Third, employer-based insurance policies should be restructured to provide greater financial protection for workers in small and medium-sized enterprises, including through tax incentives, pooled purchasing arrangements, or state-supported group plans. Finally, federal innovation funding should be paired with equity-based requirements designed to support the diffusion of technology to safety-net settings, community health centers, and rural facilities.

## Limitations

The present study relies exclusively on publicly available secondary data sources, which limits the level of control over the accuracy, completeness, and consistency of the variables examined. Because the study is cross-sectional, it captures national spending and access patterns at a single point in time. It therefore cannot establish causality among innovation, access, and health outcomes. Additionally, this study does not include individual-level patient data and, therefore, cannot assess behavioral patterns, clinical decision-making, or the lived experiences of affected populations. State-level disparities may also be underestimated due to variations in reporting methods across agencies. Finally, the study's reliance on aggregated, national indicators limits its ability to identify more granular differences across demographic groups, regions, or specific clinical populations.

## Future Research

Future studies should expand on these findings through longitudinal research examining how changes in innovation spending and coverage policies influence outcomes over time. A mixed-methods approach would allow researchers to integrate quantitative trends with qualitative insights from clinicians, policymakers, and patients affected by affordability barriers. Additional comparative research incorporating international health systems may also yield valuable lessons on cost control, equity, and improved outcomes. Further, studies focusing on organizational strategies, particularly among SMEs, could clarify how employer policies mediate access to innovation. Finally, a deeper examination of affordability mechanisms, including cost-sharing reforms and network adequacy standards, is needed to determine which policy interventions most effectively reduce disparities in access and outcomes.

## CONCLUSION

The findings of this study illustrate that the U.S. healthcare system continues to face a widening divide between medical innovation and equitable access. While decades of investment in biomedical research, digital health technologies, and advanced clinical procedures have positioned the United States at the forefront of global innovation, these advancements have not translated into proportional improvements in population health. Instead, significant inequities persist, particularly among uninsured and underinsured groups, signaling that innovation is not reaching those most vulnerable to adverse health outcomes. Quantitative evidence from this study further demonstrates that coverage rates and affordability barriers are more predictive of health outcomes than innovation spending alone, reinforcing the reality that technological progress is ineffective when a substantial portion of the population cannot practically access care.

This disparity highlights a critical national challenge: scientific progress cannot compensate for structural inequities in access. Insurance instability, rising out-of-pocket costs, and limited provider availability in underserved communities prevent millions from benefiting from innovations designed to improve health and prevent disease. Without addressing these structural gaps, innovation becomes concentrated among resource-advantaged populations, deepening rather than reducing inequity. Moreover, this imbalance underscores the urgency of shifting healthcare leadership and policy priorities toward equity-driven models that emphasize affordability, comprehensive coverage, and access to preventive services.

As a result, reforms must go beyond funding innovation; they must also strengthen the mechanisms that make innovation accessible. This includes expanding insurance coverage, reducing financial barriers to care, and addressing geographic disparities in provider distribution. Employers, especially small and medium-sized enterprises, must be supported through affordable, sustainable benefit structures so that workers are not excluded from preventive and primary care services. Ultimately, innovation must be integrated with policies that protect individuals from financial and systemic barriers if the nation hopes to reverse current disparities in preventable illness and premature mortality. Aligning innovation with comprehensive access reforms is essential to ensuring that breakthroughs in science genuinely improve the health of all Americans, not just those who can afford them. Only by pairing innovation with equitable access can the U.S. healthcare system fulfill its transformative potential at the population level.

## REFERENCES

1. Adams, J. S. (1965). Inequity in social exchange. *Advances in Experimental Social Psychology*, 2, 267–299. Academic Press. [https://doi.org/10.1016/S0065-2601\(08\)60108-2](https://doi.org/10.1016/S0065-2601(08)60108-2)
2. Centers for Disease Control and Prevention. (2024, October 29). Health outcomes: PLACES data. U.S. Department of Health and Human Services. <https://www.cdc.gov/places/measure-definitions/health-outcomes.html>
3. Centers for Medicare & Medicaid Services. (2024). National health expenditure data. U.S. Department of Health and Human Services. <https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data>
4. Commonwealth Fund. (2024). 2024 state health system performance scorecard. <https://www.commonwealthfund.org>
5. Creswell, J. W., & Creswell, J. D. (2018). *Research design: Qualitative, quantitative, and mixed methods approaches* (5th ed.). SAGE Publications.
6. Field, A. (2018). *Discovering statistics using IBM SPSS statistics* (5th ed.). SAGE Publications.
7. Girvan, G. (2024). Key findings from the 2024 World Index of Healthcare Innovation. Foundation for Research on Equal Opportunity. <https://freopp.org/whitepapers/key-findings-from-the-2024-world-index-of-healthcare-innovation/>
8. JPMorgan Chase Institute. (2024). The impact of rising healthcare costs on small business payroll and employment outcomes. JPMorgan Chase & Co. <https://www.jpmorganchase.com/institute/research/healthcare-small-business>

9. Kaiser Family Foundation. (2024). How much do people with employer plans spend out-of-pocket on cost-sharing? KFF. <https://www.kff.org/health-costs/how-much-do-people-with-employer-plans-spend-out-of-pocket-on-cost-sharing/>
10. Mick, S. S., & Shay, P. D. (Eds.). (2014). *Advances in health care organization theory* (2nd ed.). Jossey-Bass.
11. Organisation for Economic Co-operation and Development. (2024). *Health at a glance: OECD indicators 2024*. OECD Publishing. <https://www.oecd.org/health>
12. Office of the Assistant Secretary for Planning and Evaluation. (2024, June). Improving access to affordable and equitable health coverage: A review of the period from 2010 to 2024 (Issue Brief No. HP-2024-11). U.S. Department of Health and Human Services. <https://aspe.hhs.gov/reports/improving-access-affordable-equitable-health-coverage>
13. Office of the Assistant Secretary for Planning and Evaluation. (2025, February). Health insurance coverage and healthcare access trends, 2021–2024. U.S. Department of Health and Human Services. <https://aspe.hhs.gov/reports/coverage-access-2021-2024>
14. Papanicolaos, I., Niksch, M., & Figueroa, J. F. (2025). Avoidable mortality across U.S. states and high-income nations. *JAMA Internal Medicine*. Advance online publication. <https://pubmed.ncbi.nlm.nih.gov/40126499/>
15. Rogers, E. M. (2003). *Diffusion of innovations* (5th ed.). Free Press.
16. Schneider, E. C., Shah, A., Doty, M. M., Tikkanen, R., Fields, K., & Williams, R. D. (2024). *Mirror, mirror 2024: How the U.S. health care system compares internationally*. The Commonwealth Fund. <https://www.commonwealthfund.org>
17. The Commonwealth Fund. (2024). Trends in employer health insurance costs, 2014–2023. <https://www.commonwealthfund.org/publications/issue-briefs/2024/dec/trends-employer-health-insurance-costs-2014-2023>
18. Tikkanen, R., & Abrams, M. K. (2020). U.S. health care from a global perspective, 2019: Higher spending, worse outcomes? The Commonwealth Fund. <https://www.commonwealthfund.org>
19. Tolbert, J., Cervantes, S., Bell, C., & Damico, A. (2024, December 18). Key facts about the uninsured population. KFF. <https://www.kff.org/uninsured/key-facts-about-the-uninsured-population/>
20. U.S. Census Bureau. (n.d.). Health insurance coverage data. U.S. Department of Commerce. <https://data.census.gov>